Compare NYAX & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | ALMR |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2022 | 2026 |
| Metric | NYAX | ALMR |
|---|---|---|
| Price | $43.76 | $34.15 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $49.50 | N/A |
| AVG Volume (30 Days) | 22.7K | ★ 284.2K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | N/A |
| Revenue Next Year | $21.70 | N/A |
| P/E Ratio | $89.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.17 | $21.58 |
| 52 Week High | $76.86 | $38.54 |
| Indicator | NYAX | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 31.44 | 65.19 |
| Support Level | N/A | $23.69 |
| Resistance Level | $69.85 | $38.54 |
| Average True Range (ATR) | 1.08 | 2.16 |
| MACD | -0.30 | 0.15 |
| Stochastic Oscillator | 8.21 | 70.50 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.